—
Summary‘Gastric Ulcers - Pipeline Review, H2 2016’, provides an overview of the Gastric Ulcers pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/685902-gastric-ulcers-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers
- The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastric Ulcers
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685902-gastric-ulcers-pipeline-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastric Ulcers Overview 6
Therapeutics Development 7
Pipeline Products for Gastric Ulcers - Overview 7
Gastric Ulcers - Therapeutics under Development by Companies 8
Gastric Ulcers - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Gastric Ulcers - Products under Development by Companies 11
Gastric Ulcers - Companies Involved in Therapeutics Development 12
Ache Laboratorios Farmaceuticos S/A 12
Astellas Pharma Inc. 13
ChoDang Pharm Co., Ltd. 14
Kukje Pharmaceutical Industry Co., Ltd. 15
XuanZhu Pharma Co., Ltd. 16
Gastric Ulcers - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 25
(ecabet + ranitidine) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
anaprazole sodium - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ASP-6537 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
KJ-14001 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PDI-39 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PMKS-005 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules for Gastric Ulcers - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Gastric Ulcers - Dormant Projects 32
Gastric Ulcers - Discontinued Products 33
Gastric Ulcers - Product Development Milestones 34
Featured News & Press Releases 34
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 34
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 35
Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 35
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 35
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 36
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 37
Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court 37
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 38
Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals 38
Oct 23, 2001: Prilosec US litigation 39
May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec 39
May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent 39
Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement 39
Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada 40
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685902
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140099
Google
RSS